1/9
11:53 am
hrtx
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.